Towards optimizing cefepime/tazobactam (WCK 4282) exposure to achieve efficacy against piperacillin/tazobactam-resistant ESBL infections: dose recommendations for various renal functions, including intermittent haemodialysis, in healthy individuals
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Anouk E Muller und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, Haaglanden Medisch Centrum, The Hague, The Netherlands. Hauptthemen laut MEDLINE: Cefepime, Anti-Bacterial Agents, Microbial Sensitivity Tests, Piperacillin, Tazobactam Drug Combination. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Wockhardt Ltd.
Abstract (Originalsprache)
Objectives
WCK 4282 is a novel combination of cefepime 2 g and tazobactam 2 g being developed for the treatment of infections caused by piperacillin/tazobactam-resistant ESBL infections. The dosing regimen for cefepime/tazobactam needs to be optimized to generate adequate exposures to treat infections caused by ESBL-producing pathogens resistant to both cefepime and piperacillin/tazobactam.
Methods
We developed pharmacokinetic population models of cefepime and tazobactam to evaluate the optimal dose adjustments in patients, including those with augmented renal clearance as well as various degrees of renal impairment, and also for those on intermittent haemodialysis. Optimal doses for various degrees of renal function were identified by determining the PTA for a range of MICs. To cover ESBL-producing pathogens with an cefepime/tazobactam MIC of 16 mg/L, a dosing regimen of 2 g q8h infused over 1.5 h resulted in a combined PTA of 99% for the mean murine 1 log10-kill target for the cefepime/tazobactam combination.
Results
We found that to adjust for renal function, doses need to be reduced to 1 g q8h, 500 mg q8h and 500 mg q12h for patients with CLCR of 30–59, 15–29 and 8–14 mL/min (as well as patients with intermittent haemodialysis), respectively. In patients with high to augmented CLR (estimated CLCR 120–180 mL/min), a prolonged 4 h infusion of standard dose is required.
Conclusions
The suggested dosing regimens will result in exposures of cefepime and tazobactam that would be adequate for infections caused by ESBL-producing pathogens with a cefepime/tazobactam MICs up to 16 mg/L.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Microbiology, Haaglanden Medisch Centrum, The Hague, The Netherlands.
- Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Center for Antimicrobial Treatment Optimization Rotterdam (CATOR), Rotterdam, The Netherlands.
- Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Rotterdam Clinical Pharmacometrics Group, Rotterdam, The Netherlands.
ORCID-Profile: Anouk E Muller
Förderung
- Wockhardt Ltd
Zitieren
APA
Muller, A. E., De Winter, B. C. M., & Koch, B. C. P. (2024). Towards optimizing cefepime/tazobactam (WCK 4282) exposure to achieve efficacy against piperacillin/tazobactam-resistant ESBL infections: dose recommendations for various renal functions, including intermittent haemodialysis, in healthy individuals. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae076
Vancouver
Muller AE, De Winter BCM, Koch BCP. Towards optimizing cefepime/tazobactam (WCK 4282) exposure to achieve efficacy against piperacillin/tazobactam-resistant ESBL infections: dose recommendations for various renal functions, including intermittent haemodialysis, in healthy individuals. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae076
BibTeX
@article{Muller2024,
author = {Muller, Anouk E and De Winter, Brenda C M and Koch, Birgit C P},
title = {Towards optimizing cefepime/tazobactam (WCK 4282) exposure to achieve efficacy against piperacillin/tazobactam-resistant ESBL infections: dose recommendations for various renal functions, including intermittent haemodialysis, in healthy individuals},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae076}
}
EUVIMED